APPENDIX I

ACCOUNTANTS’ REPORT

price and allocated the fixed consideration of US$250,000,000 to the units of accounting using the
relative selling price method. The consideration allocated to the license was recognized upon transfer
of the license to Celgene at contract inception and the consideration allocated to the R&D services will
be recognized over the term of the respective clinical studies for the specified indications.

For the variable considerations associated with the defined developmental, regulatory, and
commercialization goals,
the Group will allocate such variable consideration to the specific
performance obligations and recognize as revenue when the amount is no longer constrained and the
related performance obligation is satisfied. Further, the sales-based milestones and royalty payments
will be recognized as revenue at the time the subsequent sale or usage occurs.

For the year ended December 31, 2017, the Group recognized US$211,391,000 as license revenue
within collaboration revenue in the Group’s consolidated statements of operations. The consideration
allocated to the R&D services was US$38,609,000 and will be recognized over the term of the
respective clinical studies for the specified indications, of which US$1,568,000 is recognized as
research and development revenue in current period and US$37,041,000 is recorded as deferred
revenue in the balance sheet as of December 31, 2017. The Group also recognized US$16,307,000 as
opt-in R&D revenue from Celgene as the variable consideration is no longer constrained.

For the three months ended March 31, 2018, the Group recognized collaboration revenue of
US$9,294,000. The Group recognized US$7,555,000 of research and development reimbursement
revenue for the three months ended March 31, 2018 for the trials that Celgene has opted into. The
US$1,739,000 of research and development services revenue reflects the recognition of upfront
consideration that was allocated to R&D services at the time of the collaboration and is recognized
from deferred revenue as at December 31, 2017 over the term of the respective clinical studies for the
specified indications.

Merck KGaA, Darmstadt Germany

In 2013, the Company entered into a license agreement with Merck KGaA, Darmstadt Germany
for lifirafenib, which was amended and restated in 2013 and 2015, in which it granted to Merck KGaA,
Darmstadt Germany an exclusive license to develop, manufacture, and,
in certain circumstances,
commercialize lifirafenib outside of the PRC, and Merck KGaA Darmstadt Germany granted the
Company an exclusive license to develop, manufacture and commercialize lifirafenib in the PRC (the
“PRC Territory”). In March 2017, the Company regained the worldwide rights to lifirafenib after
Merck KGaA, Darmstadt Germany informed the Company that it would not exercise a continuation
option, and thus, the ex-PRC portion of the agreements terminated in their entirety, except for certain
provisions that will survive the termination. In addition, the Company is eligible for US$14,000,000
of additional payments upon the successful achievement of pre-specified milestones in the PRC
Territory. In consideration for the licenses Merck KGaA, Darmstadt Germany granted to the Company,
the Company has agreed to pay Merck KGaA, Darmstadt Germany a high single-digit royalty on
aggregate annual net sales of lifirafenib products in the PRC for a period not to exceed ten years from
the date of the first commercial sale.

— I-36 —

